创胜集团
TRANSCENTA

COMPANY PRESENTATION

August 2022

Disclaimer

- The information and opinions contained in this presentation are provided as of the date of this presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation.
- This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as “expects”, “plan”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward-looking statements contained in this presentation to reflect future events or circumstances.
- This presentation is being presented solely for your information and for your use and may not be copied, reproduced or redistributed to any other person in any manner without the Company’s prior written consent. Unauthorized copying, reproduction or redistribution of this presentation could be limited or prohibited by the securities laws of various jurisdictions. By attending this presentation, participants agree not to photograph, copy or otherwise reproduce these materials during the presentation or while in the conference room.
- The company cannot guarantee that it will be able to develop, or ultimately market, any of its drug candidates successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

TODAY'S AGENDA

01 Company Overview

02 Business Update

03 Financial Update & Outlook

04 Q&A

PART 01

Company Overview

Company Overview

Transcenta at a Glance

An Integrated Biopharma with Global Footprint



Global Vision from Inception

- **Global** rights
- **Global** IP position
- **Global** development and registrations
- CMC and manufacturing with **global standard**

Industry Leading Technology Platforms

With end-to-end capabilities across

- **Discovery & Research**
- **Product & Process development**
- **Commercial manufacturing**

Innovative Clinical Strategy & Execution

- **Optimize** the clinical trial design
- **Flawless execution** worldwide

World-Class CMC Team & CDMO Capability

- **IND & BLA Filing**
- **Commercial launch readiness**
- **CDMO business**

Company Overview

Seasoned Management Team and World-class Scientific Advisory Board

Xueming Qian, Ph.D.
Co-Founder and CEO

AMGEN

Frank Ye, Ph.D.
EVP, COO

AMGEN gsk

Caroline Germa, M.D.
EVP, Global Medicine Development and CMO

AstraZeneca Bristol Myers Squibb NOVARTIS Pfizer Lilly

Daniel Weng
EVP, CFO

AMGEN GE

Christopher Hwang Ph.D.
EVP, CTO

SANOFI GENZYME

Jerry Yang, Ph.D.
EVP, Global Process & Product Development

MSD AMGEN

Yi Gu, Ph.D.
SVP, Head of Research

Ambrx AstraZeneca

Wen-I Chang, Ph.D.
SVP, Oncology Franchise Strategy

Lilly gsk

Kevin Lin
SD, Corporate Strategy & BD

City of Hope 達晨創投

Briggs Morrison, M.D.

Scientific Advisory Board Chairman
Executive Partner | MPM Capital
President | Syndax Pharma
Former CMO | AstraZeneca
Former Head of Clinical Development | Pfizer

Susan Jerian, M.D.

President & CEO | ONCORD INC.
Former Supervisory Medical Officer | CBER, FDA
Former Director Clinical Research | Amgen Inc.

Pasi A. Jänne, M.D., Ph.D.

Director | Lowe Center for Thoracic Oncology
Director | Belfer Center for Applied Cancer Science
Professor | Harvard Medical School

Ling Su, Ph.D.

Professor & Director | Institute of Drug Regulatory Science, Shenyang Pharmaceutical University
Venture Partner | Lilly Asia Ventures

Li Xu, M.D. MBA

Strategic advisor to CEO
Venture Partner, LAV
Former VP, Clinical Development, Pfizer
Former Head of Oncology Development, Hengrui

Strong Global Clinical Development Team

Experienced and Outstanding Leader

Dr. Caroline Germa, M.D.

EVP

Global Medicine Development and CMO

- An accomplished medical oncologist and medicine development.
- Over 20 years of pharmaceutical experience across the spectrum of drug development, **from early clinical trials to late phase and registration**.
- Prior to joining the **Transcenta**, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for **AstraZeneca**'s oncology department. During her time at AstraZeneca, Dr. Germa built an Early Development Clinical Group with over 180 staff and guided the clinical development of the early oncology portfolio.
- Immediately prior to joining AstraZeneca, she worked for **Bristol Myers Squibb** and served as the Vice President of BMS Oncology and Development Team Lead for a major partnered oncology program.
- Before joining BMS, Dr. Germa spent seven years at **Novartis**, and led the late phase clinical development of multiple key oncology assets, especially the worldwide registration strategy and approval of Ribociclib (**CDK4/6 inhibitor - Kisqali**).
- Earlier in her career, she also worked for **Pfizer** as its clinical lead for **Neratinib (anti-HER2 inhibitor, Nerlynx)**, as well as **Eli Lilly France and Sanofi/Aventis**.

Diversified and Differentiated Pipeline

1H	Drug candidate	Target	indications	Clinical trial region	Preclinical	IND	Phase 1a	Phase 1b/ Phase 2a	Pivotal Phase 2b / Phase3	Rights	Partner
Oncology	TST001	Claudin 18.2	First-line G/GEJ cancer	Global	Combo with chemo					Global	In-house
			Late-line GC	China	Monotherapy						
			Late-line PDAC	Global	Monotherapy						
			Other late-Line solid tumors	Global	Monotherapy						
			Second-line GC	Global	Combo with chemo						
			First-line G/GEJ cancer	Global	Combo with Nivolumab/Chemo						
			2/3 Line G/GEJ cancer	Global	Combo with Nivolumab						
			First-line BTC	Global	Combo with chemo						
	TST005	PD-L1/TGF-β Bi-functional	Solid tumors (HPV+ and NSCLC, etc.)	Global	Monotherapy					Global	In-house
	TST003	BMP Antagonist (FIC)	Solid tumors	Global	Monotherapy					Global	In-house
	TST006	Claudin 18.2/PD-L1 Bi-specific (FIC)	Solid tumors	Global	Monotherapy					Global	In-house
	TST010	Undisclosed	Solid tumors	Global	Monotherapy					Global	In-house
	MSB0254	VEGFR2	Solid tumors	China	Monotherapy					Global	In-house
	MSB2311	PD-L1	TMB-H solid tumors	China	Monotherapy					Global	In-house
			Solid tumors	China	Combo with VEGFRi						
Non-oncology	TST002	Sclerostin	Osteoporosis	China	Monotherapy			US Ph II Completed		Greater China	Lilly
	TST004	MASP2	IgA nephropathy TMA	Global	Monotherapy					Global	ALEBUND
	TST008	MASP2-based Tri-functional (FIC)	SLE	Global	Monotherapy					Global	In-house

PART 02

Business Update

1H 2022 Business Highlights

5 FIC/BIC programs

- **3 programs** in ongoing clinical trials
- **2 new programs** with IND enabling studies completed
- **10+ Pipeline Programs**
  - **Solid tumors**
  - **Osteoporosis**
  - **IgA nephropathy/TMA**
  - SLE

5 Global R&D Sites

- New Jersey, US
- Suzhou, China
- Shanghai, China
- Beijing, China
- Hangzhou, China

4 Core Technologies & CDMO Business

- **IMTB** Platform
- **Translational/CDx**
- **Continuous BioProcessing**

FIC: First in Class; BIC: Best in Class; IND: Investigational new drug; IgA nephropathy: Immunoglobulin A nephropathy; TMA: Thrombotic microangiopathy; IMTB: Immune Tolerance Breaking; CDx: Companion diagnostics

Business Update

Pipeline Highlights

Technology Platforms: IMTB, Bispecific, Continuous Bioprocessing, etc

- ✓ **TST001**
  (Best-In-Class) CLDN18.2
- ✓ **TST005**
  (Best-In-Class) PDL1-TGF-β
- ✓ **MSB0254**
  (Differentiated) VEGFR2
- ✓ **TST003**
  (First-In-Class) Novel Target



- ✓ **TST002**
  (Differentiated) Sclerostin
- ✓ **TST004**
  (Best-In-Class) MASP2
- ✓ **TST008**
  (First-In-Class) Bispecific

Oncology:
Multiple solid tumors

+

Non-Oncology : large unmet needs in bone and kidney diseases

TGF-β: Transforming growth factor beta; PDAC: Pancreatic ductal adenocarcinoma cancer; BTC: Biliary Tract Carcinoma; CRC: Colo-rectal carcinoma; NSCLC: Non-small cell lung cancer; GC: Gastric cancer; ESCC: Esophageal squamous cell carcinoma; PC: Prostate cancer; BC: Breast cancer; SLE: Systemic lupus erythematosus

Performances

1H/22-Strong Performance in Pipeline Advancement and Business Operations

Deepening and broadening the pipeline and advancing growth initiatives

Clinical Development of TST001

Favorable data | MNC CDx partner | Regulatory approval

Monotherapy

- ✓ Data presented at **2022 ASCO GI**
- ✓ Data presented at the **2022 IGCC**

Combo with chemo

- ✓ Enrolled patients of TST001/CAPOX combo cohort of 1L GC
- ✓ **Dosed 1st patient** in the Phase IIa study of chemo combo for 1L BTC
- ✓ Data presented at **2022 ASCO**

Combo with Nivolumab

- ✓ Clinical Trial Collaboration with **BMS**

Business Development

Favorable data readouts to enhanced negotiating position in discussion for partnerships

TST001

- ✓ Global clinical trial collaboration with **BMS** to evaluate the combination of TST001 with Opdivo® (nivolumab)

TST003

- ✓ In collaboration with the teams at **Hospital and University** and published the results of preclinical studies in **Nature Cancer**

Other Clinical Developments

MRCT and experienced teams in China and the US | Next wave of innovation with FIC/BIC potential

TST005

- ✓ Data presented at the **AACR annual meeting 2022**
- ✓ Completed the evaluation of first two cohorts
- ✓ Opened **China site**

MSB0254

- ✓ Data presented at **2022 ASCO**

TST003

- ✓ Completed IND enabling studies and dossiers for US IND filing;
- ✓ Published the results in **Nature Cancer**

TST002

- ✓ **Dosed 1st patient**

TST004

- ✓ Completed IND enabling studies and dossiers for US IND filing;
- ✓ Data Presented at the **2022 ISN Frontiers Meetings**

CMC & CDMO

Significantly increased operational efficiency and productivity

Capability and capacity

- ✓ Commercial process change accepted by **FDA** & **CDE**;
- ✓ **Passed audit by European Union QP**
- ✓ Advanced ICB platform
- ✓ Added >15 **new clients** and expanded **new service categories**

Business Update

Oncology

TST001: Product Profile

The 2nd Leading Anti-CLDN18.2 mAb with A Differentiated Profile vs. Zolbetuximab and BIC/FIC Potentials

BIC / FIC Potentials by Design and confirmed by Pre-clinical data

- *Higher binding affinity with CLDN18.2*
- *Reduced fucose in Fc and enhanced FcR binding with NK cell and ADCC activity*
- *Combo potential with Immunotherapy, angiogenic inhibitor and chemo.*
- *Proprietary CDx tool antibody with high specificity to CLDN18.2*

Enhanced ADCC activity for CLDN18.2 low expressing gastric cancer cells



Significantly better in vivo anti-tumor activity than IMAB362 analog

Synergy with PD-1 inhibitor

MKN45-CLDN18.2 (40%) Gastric Tumor Model



7/10 in TST001 Group vs. 0/10 in IMAB362 Group Achieved Tumor Clearance

CLDN18.2 (>95%)/PDL1-Negative PDX Model



Data on file

CLDN18.2 (100%)/PDL1 Syngeneic Model



TST001: IHC Assay

Developed CLDN18.2 Specific Companion Diagnostic Assay



GC182: Transcenta produced based on publicly available information. 40x



Negative nonspecific staining - (≤1) at A – 10x, B – 20x, C – 40x

Tumor-membrane staining of GC at Left– 10x, Mid– 20x, Right– 40x

- Transcenta discovered and developed a mouse mAb (clone 14G11) that binds to CLDN18.2 specifically and distinguishes CLDN18.2 from CLDN18.1 while competitor's antibody can't
- Collaborated with a global Companion diagnostic (CDx) developer for the development of CLDN18.2 companion diagnostic kit and demonstrated its specificity, robustness, and commercial viability

Business Update

TST001 : Trial Plan and Milestones

Global Program to Expand Indications beyond Gastric and Pancreatic Cancers

Oncology

Single Agent				Combo Study						
Late line gastric cancer	Late line pancreatic cancer	Late line biliary tract cancer	Late line solid tumor	Late line Gastric cancer (+PD1)	2nd line plus Gastric Cancer (+PD1)	2nd line Gastric Cancer (+TAXOL)	1st line Gastric Cancer (+CAPOX)	1st line Gastric Cancer (PD1+CAPOX)	1st line Pancreatic Cancer (+GemNab)	1st line Biliary Tract Cancer (+GemCis)
√	√	√	√	√	√	√	√	√	√	√
Fast to market							Market Expansion			
Potential Pivotal Trials In Late Line Indications							Potential Pivotal Trials in First Line Indications			

Milestones in 1H/22

January

- ✓ **1st patient** enrolled and dosed in Phase II trial in BTC
- ✓ U.S. Phase I trial TIP abstract presented at **2022 ASCO GI**

February

- ✓ **Dosed 1st patient** in the Phase IIa study of chemo combo for 1L BTC

March

- ✓ China Phase I trial dose-escalation part data presented at the **IGCC**
- ✓ A global clinical **collaboration with BMS** to evaluate the combination of TST001 with Opdivo® (nivolumab) for G/GEJ cancer

April

- ✓ **Passed audit of European Union QP** prepared for a global Phase III clinical trial application

June

- ✓ Data for the dose-escalation of the Phase I chemo combo study for 1L G/GEJ cancer presented at **ASCO 2022**

Combo: Combination; Chemo: Chemotherapy; G/GEJ cancer: Gastric cancer or gastroesophageal junction cancer

Business Update

TST001: Phase I Study-Monotherapy (Anti-claudin18.2 Monoclonal Antibody) in Patients with Solid Tumors

Oncology

Objectives and Methods

Dose Escalation Phase

TST001 3mg/kg Q3W → TST001 6mg/kg Q3W → TST001 10mg/kg Q3W

Dose expansion phase

Cohort A
G/GEJ No SOC or intolerable to SOC
CLDN18.2 expression

Cohort B
Pancreatic cancer
No SOC or intolerable to SOC
CLDN18.2 expression

Cohort E
BTC/CRC/NSCLC
No SOC or intolerable to SOC
CLDN18.2 expression

IGCC 2022
HOUSTON ★ TEXAS

Results



- *Male, 42-year-old, GC/peritoneal metastasis*
- *Claudin18.2 moderate expression per local test*
- *C1D1 with TST001 at 6mg/kg Q3W*
- *PR achieved at the 1st tumor assessment 6 weeks after study treatment initiation*
- *PR confirmed via the 2nd scan at 12 weeks*
- *The subject experienced appetite increase and weight gain (+3kgs) after starting TST001 treatment*

Business Update

Oncology

TST001: Phase 1 Study-Combination Therapy

CLDN 18.2 In Combination with CAPOX for 1L G/GEJ Cancer

Study Design of Cohort C

Dose Escalation				Expansion
TST001 1mg/kg +CAPOX Q3W N=3-6	TST001 3mg/kg +CAPOX Q3W N=3-6	TST001 6mg/kg +CAPOX Q3W N=3-6	TST001 8mg/kg +CAPOX Q3W N=3-6	TST001 +CAPOX Q3W N=30

2022 ASCO® ANNUAL MEETING
ADVANCING EQUITABLE CANCER CARE THROUGH INNOVATION

Encouraging Preliminary Safety and Efficacy

TEAEs by SOC and PT in the Dose Escalation & Expansion Phase (≥20% patients)

	1 mg/kg n=3	3 mg/kg n=3	6 mg/kg n=15	8 mg/kg n=5	Overall n=26
Subjects with at least one TEAE	3 (100)	3 (100)	15 (100)	5 (100)	26 (100)
Nausea	3 (100)	2 (66.7)	12 (80.0)	5 (100)	22 (84.6)
Hypoalbuminaemia/hypoproteinemia	2 (66.7)	2 (66.7)	10 (66.7)	4 (80.0)	18 (69.2)
Anaemia	3 (100)	3 (100)	8 (53.3)	2 (40.0)	16 (61.5)
Vomiting	1 (33.3)	2 (66.7)	7 (46.7)	4 (80.0)	14 (53.8)
Aspartate aminotransferase increased	2 (66.7)	3 (100)	6 (40.0)	0	11 (42.3)
Decreased appetite	1 (33.3)	0	6 (40.0)	2 (40.0)	9 (34.6)
Hyponatraemia	1 (33.3)	2 (66.7)	4 (26.7)	2 (40.0)	9 (34.6)
Alanine aminotransferase increased	2 (66.7)	3 (100)	4 (26.7)	0	9 (34.6)
Oedema peripheral	1 (33.3)	2 (66.7)	4 (26.7)	0	7 (26.9)

- *Mostly **grade 1-2 treatment emergent adverse events**.*
- *Some responses observed in **CLDN18.2 unselected** who had measurable lesions and at least one post-treatment tumor assessment*
- ***The updated data from chemo combo expansion cohort to be presented at ESMO 2022***

Best changes (%) from baseline of target lesions in dose escalation phase



5 *out of* **9** *patients achieved PR*

3 *out of* **9** *patients achieved SD*

Business Update

TST005: Highlights

A PDL1-TGFβ Trap Bi-functional Antibody

Oncology

Anti-PDL1



TGFβ trap

	TST005	M7824
MOA	Dual inhibition of PD1-PDL1 Interaction and TGF-β pathway	
Preclinical Differentiation	• FcR binding silenced • No ADCC activity • Improved PK/PD	FcR binding retained ADCC activity
Clinical Differentiation	Biomarker selected for TGF-β pathway activated tumors	All comer without enriching TGF-β pathway activated tumors
Territory	Both US and China	Global

Target

- PD-L1/TGF-β Bi-functional
- Highly expressed in PD1 refractory tumors (NSCLC, H&NSC, GC)

Molecular Differentiation

- Fc-silenced IgG1 backbone vs. WT Fc for M7824
- Proprietary high affinity anti-PD-L1
- Different TGF-β trap moiety with improved stability vs. M7824

Development Milestone

- Global Phase I ongoing in both US and China
- 3rd dose escalation cohort completed

Increased TGFβ Blocking in Tumor and Improved Tumor Growth Inhibition in EMT/hPDL1 Mice





Business Update

MBS0254 Highlights:

A Humanized VEGFR2 mAb Candidate for Solid Tumors

Oncology

- **Blocks binding of VEGF-A and VEGF-C to VEGFR2 and normalizes vasculature in tumor microenvironment**
- **MSB0254 enhanced the activities of immunotherapy and targeted therapy like TST001**
- **Currently completed dose-escalation study and determined RP2D**

MOA: Attractive Molecule for Targeted Therapy



Potential Combination Opportunity with TST001



**: vs isotype control p<0.01; ##: vs TST001 p<0.01; &&: vs DC101 P<0.01

DC101 is a surrogate mAb to mVEGFR2

Milestones

2022.6_: Published data of Phase I study in Chinese Solid Tumor Patients at 2022 ASCO

VEGFR: Vascular endothelial growth factor receptor

Business Update

TST003 Highlights:

FIC mAb with Antitumor Activities in Multiple Tumor Models

Oncology





Green： Stromal fibroblast

Dongre, A., et al Cancer Discovery 2020 DOI: 10.1158/2159-8290.CD-20-0603



nature cancer

nature cancer ARTICLES

https://doi.org/10.1038/s43018-022-00380-3

Check for updates

Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer

Chaping Cheng[1,7], Jinming Wang[1,7], Penghui Xu[1], Kai Zhang[1], Zhixiang Xin[1], Huifang Zhao[1], Zhongzhong Ji[1], Man Zhang[2], Deng Wang[1,2], Yuman He[1], Na Jing[1,2], Liancheng Fan[1], Kaiyuan Liu[1], Fei Li[3], Chengcheng Liu[1], Yiming Gong[1], Suli Cui[4], Zhe Sun[4], Di Sun[4], Xinlai Yao[4], Hongjun Li[4], Jian Zhang[5], Pengcheng Zhang[6], Baijun Dong[1], Wei Xue[1], Xueming Qian[4], Wei-Qiang Gao[1,2] and Helen He Zhu[1]

Target

- Target Gremlin1, a negative regulator of the BMP signaling pathway
- Highly expressed in stromal cells in tumor microenvironment of multiple tumor types (NSCLC, CRC, ESCC, GC, BC, PC, etc)

Molecule

- A high affinity humanized antibody that can enhance BMP signaling in tumor and promote differentiation
- Significant antitumor activities in preclinical studies as mono or combo therapy with CPI and/or other anti-tumor agents.
- Potential applications for multiple PD-L1 negative solid tumors

Milestones

- Published the preclinical results for AR low/negative Prostate Cancer in Nature Cancer
- Gremlin1-specific antibodies can **effectively control tumor growth** in androgen receptor-negative/low prostate cancer.
- Single agent and combination antitumor activities demonstrated in multiple PDX models including CRC

Outlook

- US IND filed in Aug/2022

BMP: Bone morphogenetic protein; PDX: patient derived xenografts

Business Update

TST002 : A Well Differentiated Monoclonal Antibody for Bone Diseases

Licensed from Eli Lilly with Phase II Data in US and Japan

Non-oncology

Dual Mechanism of Bone Formation and Anti-Resorption



Favorable Product Characteristics Throughout Value Chain

Product	Blosozumab / TST002 (Phase II conducted by Eli Lilly
EFFICACY	• Statistically significant dose-dependent BMD increase in spine, femoral neck, and total hip as compared with placebo • In the highest dose group, BMD increased from baseline by **17.7%** at the spine, and **6.2%** at the total hip, within 12 months of treatment
SAFETY	• **No cardiovascular risk observed**
DOSING	• **Once 2-3 months IV dosing** • **Improved patient compliance**
BENEFITE	• **Lower COGS and better affordability** for China patients
MILESTONE	• Dosed first patient in **China Phase I study in April 2022**

Business Update

TST004 :An Anti-MASP2 Antibody with Favorable Lectin Pathway Inhibition

Potential Applications to Multiple MASP2-dependent Complement Mediated Diseases, including IgAN, A Highly Prevalent Chronical Kidney Disease

Non-oncology

Superior Product Profile

Dosing	• Subcutaneous formulation • Potentially less frequent dosing
Binding affinity	• High binding affinity • Specific to MASP-2 in the Lectin pathway
PK/PD	• Long lasting target inhibition in cynomolgus monkey
Dev. plan	• Co-develop with Alebund in China • File US IND in August 2022

Multiple Potential Indications



C3 Glomerulopathy (C3G)
IgA nephropathy (IgAN)
Lupus nephritis
Membranous nephropathy (MN)
Atypical Haemolytic Uraemic Syndrome (aHUS)

Age-Related Macular Degeneration (AMD)
Recessive Stargardt Disease (STGD1)
Uveitis

Paroxysmal Nocturnal Haemoglobinuria (PNH)
Autoimmune Haemolytic Anaemias (AIHA)
Thrombotic Microangiopathy (TMA)

Virus infection trigged complements over-action in multi organ injury

Nature Reviews Immunology 2009
Mol Immunol. 2018 Oct;102:89-119.

Milestone

JV with ALEBUND in 2021

- *Presented the preclinical data at the 2022 ISN Frontiers Meetings of Complement-Related Kidney Diseases*
- *Planned US IND filing in 2022*

Business Update

Discovery & Translational Research:

Proprietary Antibody Discovery Platform Delivers Candidates with Superior Profiles

IMTB Platform Advantages



Hidden epitope

Hidden epitopes that are challenging to discover with conventional platforms

Difficult-to-generate epitope

Antibodies to both non-conserved and conserved proteins



- ✓ More diversified epitopes
- ✓ More differentiated antibody with enhanced drug attributes
- ✓ Robust CMC profiles
- ✓ Enhanced IP position

Potential FIC & BIC Molecules Discovered

TST001 (BIC, CLDN18.2)

A potent therapeutic candidate co-developed with specific CDx

- ✓ **Target is a highly conserved membrane protein**
- ✓ **Enhanced ADCC mediated tumor-killing**
- ✓ **Potentially boarder cancer indications than peers**

TST003 (FIC, Gremlin1)

A therapeutic candidate targeting a novel immune regulatory protein produced by stromal fibroblasts

- ✓ **Target is highly conserved secreted protein**
- ✓ **Significant anti-tumor activities in castrate resistant prostate cancer and multiple PD-L1 negative PDX models**
- ✓ **Potential to address high unmet needs for multiple solid tumors**

Business Update

CMC & CDMO:

Flawless Execution with Increased Efficiency and Commercial Launch Readiness

Advance manufacturing platform to increase speed, quality and lower costs

- **Industry Leading** perfusion productivity **of > 6 g/L-day, > 15-fold** increase in output
- Scaled up TST001 intensified perfusion GMP process to **commercial scale**
- Completed **Industry's first** automated flow-through polishing continuous DSP equipment (Combo), co-developed with **Merck**

✓ Commercial process change to intensified perfusion accepted by **FDA** and **CDE**; output increased by **> 8-folds**
✓ Passed audit by **European Union QP**
✓ Achieved > **7 g/L-day** perfusion productivity; readiness of **Merck Combo** on track



Excellence in execution, expanding capacity

- **100% success rate** in project execution since Q4/19
- Added **2,000L** SUB and a DP fill line
- Commercial launch prep from **T-BLOC** in progress
- Secured land for future capacity expansion

High quality CDMO services

- Intensified platforms to **maximize productivity**
- **External revenue** since 2018 to offset expenditure

✓ **> 15 new clients** and expanded **new service categories** in analytical testings and DP fills

SUB: single use bioreactor

Business Update

Business Development

Multinational Partners to Maximize Asset Value and Increase Productivity

Collaborations

TRANSCENTA INNOVATE TO EXCEL

Bristol Myers Squibb™

Trials Sponsor

Opdivo Provider

Clinical Trial Collaboration

TST001 + Opdivo® (nivolumab)

For the treatment of patients with CLDN 18.2 positive G/GEJ cancer, generating data to lead a new treatment paradigm in 4-5 years

Lilly

Blosozumab Anti-sclerostin mAb

Anti-RANKL-PTH mAb-peptide fusion

Anti-RANKL/DKK1 Bi-specific

In-License

Dana-Farber Cancer Institute

北京大学肿瘤医院 BEIJING CANCER HOSPITAL

上海交通大学 SHANGHAI JIAO TONG UNIVERSITY

上海市肺科医院 SHANGHAI PULMONARY HOSPITAL

Research Collaboration

TRANSCENTA INNOVATE TO EXCEL MERCK

Develop highly intensified and efficient downstream to de-bottleneck and maximize facility output

Technology-based Partnership

ALEBUND

Develop and commercialize TST004 in **renal diseases** in Greater China

Joint Venture

PART 03

Financial Update & Outlook

Healthy Financial Profile and Well Capitalized for Growth Initiatives

Cash Balance

RMB 1,138 million of cash,

cash equivalents and time deposits as of June 30, 2022

Key Income Statement Metrics

- **Revenue:** RMB 21.8 million
- **Other Income:** RMB 23.9 million
- **R&D expenses** (non-IFRS): RMB 165.8 million
- **General, Administrative and Selling Expenses** (non-IFRS): RMB 57.4 million

Outlook

Integrated Platform, Cutting-edge Technology, Differentiated and Competitive Biologics

Clinical Development

Oncology

TST001

- Q3 2022 Present interim data from Phase IIa chemo combo cohort of CLDN18.2 positive 1L G/GEJ cancer at ESMO
- Q3 2022 Initiate TST001/Nivolumab combo trials for 1L & late line G/GEJ cancer
- 1H 2023 Interim data readout from Phase IIa monotherapy cohort of CLDN18.2 selected late line G/GEJ cancer
- 1H 2023 Initiate a global TST001/Chemo combo Phase III registration trial in CLDN18.2 overexpressing 1L G/GEJ cancer pending health authority consultations
- Q4 2023 Interim data readout from Phase IIa TST001/Nivolumab combo cohorts in G/GEJ cancer

	prevalent cases in China and US in 2020	5-Yr Survival Rate
Gastric Cancer	478k and 26k	32%
Esophageal Cancer	324k and 18k	20%
Pancreatic Cancer	125k and 57k	9%
Biliary tract	90k and 12k	2%

TST005

- 1Q 2023 Complete Phase Ia dose-escalation study

TST003

- Q4 2022 IND clearance in US and initiate First in Human trial

TST010

- Q1 2023 Initiate IND enabling study

Non-oncology

TST002

- 1H 2023 Complete Phase I study and release interim data

TST004

- Q3 2022 File IND in US, followed by IND filing in China

TST008

- Q1 2023 Initiate IND enabling study



Outlook

Integrated Platform, Cutting-edge Technology, Differentiated and Competitive Biologics

Global Biopharma

Research

- Expand our pipeline by having one new drug candidate entering IND enabling study each year
- Further expand translation research to enable indication expansion for TST001, TST003, TST005 and TST004

Business Development

- Continue discussions with potential partners to maximize the asset value and generate cash flow
- Focus on establishing partnerships for TST001, TST002, TST003 and TST004
- Continue to identify, evaluate and build new technology platforms through collaboration and partnership

CMC & CDMO

- Continue to develop CDMO business to fully utilize capacities and to generate income
- Complete TST001 Process Characterization and establish Process Control Strategy
- Complete readiness to start TST001 PPQ in prep for BLA filing

PART 04

Q&A

THANK YOU!

ir@transcenta.com